Respiratory Disease Vaccine Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

91.80 billion

CAGR (2023-2028)

1.18%

Fastest Growing Segment

Viral Vaccine Segment

Largest Market

Asia Pacific

 

Market Overview

Global Respiratory Disease Vaccine Market has valued at USD 91.80 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 1.18% through 2028.  Respiratory diseases, also known as respiratory disorders or lung diseases, encompass a broad category of medical conditions that affect the respiratory system. The respiratory system includes the organs and structures responsible for breathing, oxygen exchange, and carbon dioxide removal. The primary organs involved in the respiratory system are the lungs, but other components, such as the airways and muscles, also play crucial roles. Respiratory diseases can be caused by various infectious agents, including bacteria, viruses, and fungi. In addition to the flu and pneumonia, other respiratory infections include bronchitis, bronchiolitis, and tuberculosis. Allergic conditions, such as allergic rhinitis (hay fever) and allergic asthma, involve an immune response to allergens like pollen, dust mites, and animal danger. These conditions can lead to respiratory symptoms like sneezing, runny nose, and wheezing. Exposure to harmful substances in the workplace or environment can lead to respiratory diseases. Examples include asbestos-related lung diseases, coal worker's pneumoconiosis (black lung disease), and occupational asthma.

The global aging population is at a higher risk of respiratory diseases. As the elderly population grows, there is a greater need for vaccines to protect this vulnerable group. Government and healthcare organizations worldwide recommend or mandate vaccinations for certain respiratory diseases, such as influenza. These recommendations drive vaccine adoption and coverage rates. The emergence of new respiratory viruses, as witnessed during the COVID-19 pandemic, highlights the importance of preparedness through vaccination. Governments and organizations invest in vaccines as a key part of pandemic response plans. Public health campaigns and initiatives promote vaccination and raise awareness about the benefits of respiratory disease vaccines. These efforts aim to increase vaccine uptake. International organizations like the World Health Organization (WHO) and UNICEF work to expand vaccination access in low- and middle-income countries. Global immunization programs aim to reduce the burden of respiratory diseases.

Key Market Drivers

Rising Aging Population

 Elderly individuals are more susceptible to respiratory diseases and complications. As people age, their immune systems may weaken, making them more prone to infections like influenza, pneumonia, and respiratory syncytial virus (RSV). This increased vulnerability drives the need for vaccines to protect older adults. Respiratory diseases can be more severe in older adults, leading to higher hospitalization rates and mortality. Vaccines are essential for preventing these severe outcomes in the elderly population. During influenza and other respiratory disease outbreaks, the elderly are often at higher risk. Vaccinating this age group is crucial for epidemic control and reducing the overall disease burden. Pneumococcal vaccines, which protect against pneumonia and other infections caused by Streptococcus pneumoniae bacteria, are recommended for older adults. These vaccines play a vital role in preventing pneumococcal diseases.

Vaccinating the elderly is a public health strategy to reduce the societal and economic impact of respiratory diseases. It helps in lowering healthcare costs associated with disease treatment and hospitalizations. By vaccinating older adults, it not only protects them but also contributes to herd immunity. This indirectly benefits younger age groups and individuals who may not be able to receive vaccines due to medical contraindications. As life expectancy increases in many parts of the world, the elderly population becomes a more significant proportion of the total population. This demographic shift further underscores the importance of vaccination to maintain health and quality of life in older age. The demand for respiratory disease vaccines for the elderly population incentivizes pharmaceutical companies to invest in research and development to create more effective and targeted vaccines for this demographic. This factor will help in the development of the Global Respiratory Disease Vaccine Market.

Vaccine Mandates and Recommendations

Some governments and institutions have implemented vaccine mandates, requiring individuals to receive specific respiratory disease vaccines. For example, healthcare workers may be required to receive annual influenza vaccinations to reduce the risk of spreading the virus to vulnerable patients. In many countries, children are required to receive certain vaccinations before enrolling in schools or daycare centers. This includes vaccines for diseases like measles, mumps, rubella, and sometimes influenza. Such requirements ensure high vaccine coverage among school-age children. Some countries may require proof of vaccination against certain respiratory diseases, such as tuberculosis or COVID-19, for travelers or immigrants. These requirements aim to prevent the spread of diseases across borders. Certain professions, such as healthcare, may have vaccine mandates to protect both workers and patients. For example, healthcare facilities may require employees to receive vaccines against influenza, hepatitis B, or other respiratory diseases. Government health agencies and organizations like the World Health Organization (WHO) provide recommendations for vaccination against respiratory diseases. These recommendations encourage healthcare providers to offer vaccines to eligible individuals and the general population.

Health authorities often run public health campaigns to promote vaccination against respiratory diseases, particularly during flu seasons. These campaigns raise awareness about the importance of vaccination and recommend vaccination to specific populations, such as pregnant women and the elderly. During outbreaks or epidemics of respiratory diseases, health authorities may recommend or mandate vaccination to control the spread of the disease. For example, during the H1N1 influenza pandemic, vaccination campaigns were widely promoted. Recommendations often target high-risk groups, such as the elderly, young children, pregnant women, and individuals with underlying health conditions. These individuals are more susceptible to severe respiratory diseases, making vaccination crucial. Recommendations and mandates can facilitate access to vaccines by making them readily available in healthcare settings, including hospitals, clinics, and pharmacies. Encouraging vaccination in the community helps achieve herd immunity, protecting those who cannot be vaccinated due to medical reasons or contraindications. Health authorities may use epidemiological data and research to make evidence-based recommendations and mandates. These decisions are often informed by disease prevalence and severity. This factor will pace up the demand of the Global Respiratory Disease Vaccine Market.

Global Immunization Programs

Global immunization programs aim to ensure equitable access to vaccines for people in low- and middle-income countries, as well as underserved populations within high-income countries. This access extends to respiratory disease vaccines, such as those for influenza and pneumonia. These programs strive to achieve high vaccination coverage rates, including coverage for respiratory diseases. The goal is to protect as many individuals as possible against preventable respiratory infections. In response to global health threats like pandemics (e.g., COVID-19), international organizations and governments work to develop vaccination strategies and distribute vaccines on a global scale. This preparedness includes respiratory disease vaccines for pandemic control. By focusing on the prevention of respiratory diseases through vaccination, global immunization programs aim to reduce the overall burden of these diseases, including hospitalizations and mortality. Immunization programs often include targeted campaigns for specific age groups, populations at higher risk, and those in humanitarian settings. These campaigns raise awareness about respiratory disease vaccines and encourage vaccination.

Global immunization efforts include strengthening vaccine supply chains to ensure vaccines, including those for respiratory diseases, reach even the most remote and resource-limited areas. Investment in research and development of new and improved respiratory disease vaccines is often a component of these programs. This fosters innovation and the availability of more effective vaccines. Building the capacity of healthcare systems and providers in vaccine administration and surveillance is part of global immunization programs. This ensures the effective delivery of respiratory disease vaccines. Collaborations between governments, international organizations, and private-sector vaccine manufacturers are common in global immunization programs. These partnerships enhance vaccine production, affordability, and accessibility. Education and training initiatives are integral to global immunization programs. They equip healthcare workers and communities with knowledge about the importance of respiratory disease vaccination. In times of crises, such as outbreaks or natural disasters, global immunization programs can quickly mobilize resources and vaccines to protect vulnerable populations from respiratory diseases. Robust monitoring and surveillance systems are established to track vaccine coverage, adverse events, and disease trends. Data collection informs program adjustments and vaccine distribution. This factor will accelerate the demand of the Global Respiratory Disease Vaccine Market.


Download Free Sample Report

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, characterized by reluctance or refusal to receive vaccines, can lead to lower vaccination rates. When a substantial portion of the population remains unvaccinated, it leaves communities vulnerable to respiratory diseases, including influenza, pneumonia, and COVID-19. Achieving herd immunity, where a sufficient percentage of the population is immune to a disease, is crucial for protecting those who cannot be vaccinated, such as individuals with medical contraindications. Vaccine hesitancy can hinder efforts to reach herd immunity and indirectly impact vulnerable individuals. When vaccination rates drop due to hesitancy, it can lead to the resurgence of preventable respiratory diseases. Outbreaks of vaccine-preventable diseases, like measles, have occurred in areas with low vaccine coverage. Lower vaccination rates can result in increased disease transmission and outbreaks, leading to public health crises. This places additional strain on healthcare systems and resources. Misinformation and disinformation about vaccines, often spread through social media and other channels, can lead to false beliefs and fears about vaccine safety and efficacy. This can erode public trust in vaccines and healthcare authorities. Concerns about vaccine side effects, whether founded or unfounded, can contribute to hesitancy. Misinformation can amplify fears and discourage vaccination. During pandemics, like the COVID-19 pandemic, vaccine hesitancy can slow down efforts to achieve widespread vaccination coverage, making it challenging to control the spread of the virus and save lives. Persistent vaccine hesitancy can erode public confidence in the entire vaccination process and the healthcare system. This can have long-term repercussions for public health.

Supply Chain Disruptions

Disruptions in the supply chain, such as interruptions in the availability of raw materials, can lead to delays in vaccine production. This can result in vaccine shortages and affect the ability to meet demand. Supply chain disruptions can affect the timely distribution of vaccines to healthcare facilities, clinics, and pharmacies. This can lead to logistical challenges and difficulties in ensuring that vaccines reach the intended recipients. Supply chain disruptions can result in vaccines being wasted if they cannot be stored or transported properly. Temperature-sensitive vaccines, like some respiratory disease vaccines, are particularly vulnerable to wastage if cold chain integrity is compromised. Interruptions in the supply chain can impact the ability to provide vaccines to underserved regions, especially in low- and middle-income countries. This can exacerbate global health inequalities. During pandemics, like the COVID-19 pandemic, ensuring a consistent and uninterrupted supply chain for vaccines is critical. Any disruptions can slow down vaccination efforts and hinder the control of the disease's spread. Supply chain disruptions can affect the capacity of vaccine manufacturers to produce vaccines at scale. This can impact their ability to meet the demand for respiratory disease vaccines. Shortages of key raw materials, such as vials, adjuvants, and specialized equipment, can disrupt vaccine production and lead to bottlenecks in the supply chain. Transportation disruptions, including delays, restrictions, or interruptions in shipping and logistics, can hinder the movement of vaccines across regions and countries.

Key Market Trends

Pneumococcal Vaccines

Pneumococcal diseases, including pneumonia and invasive pneumococcal diseases (IPD), are associated with significant morbidity and mortality worldwide. These diseases can affect people of all ages, but they are particularly dangerous for young children and the elderly. Many countries recommended pneumococcal vaccination for specific age groups, especially young children, older adults, and individuals with certain underlying medical conditions. These recommendations drove the demand for pneumococcal vaccines. Pneumonia is a leading cause of morbidity and mortality, especially among children and older adults. Pneumococcal vaccines are effective in preventing pneumonia, making them a valuable tool in reducing the disease burden. Advances in vaccine technology led to the development of pneumococcal conjugate vaccines, which offer protection against a broader range of pneumococcal serotypes. These vaccines have been increasingly adopted in vaccination programs. Pneumococcal vaccination has shown a significant reduction in the incidence of pneumococcal diseases, leading to improved public health outcomes and reduced healthcare costs. Pneumococcal vaccines are part of pandemic preparedness efforts, as they can help reduce the burden on healthcare systems during respiratory disease outbreaks.

Segmental Insights

Type Insights

In 2022, the Global Respiratory Disease Vaccine Market largest share was held by viral vaccine segment and is predicted to continue expanding over the coming years. Viral respiratory diseases, such as influenza (flu), respiratory syncytial virus (RSV), and COVID-19, are widespread and have a significant impact on public health. These diseases can cause a wide range of respiratory infections, from mild to severe, and sometimes lead to hospitalizations and fatalities. This high prevalence drives the demand for vaccines to prevent these viral infections. Vaccination against viral respiratory diseases like influenza is a routine part of healthcare in many countries. Seasonal flu vaccination campaigns are conducted annually to protect individuals and prevent the spread of the virus, contributing to the steady demand for viral vaccines. Viral respiratory diseases often disproportionately affect elderly individuals and those with underlying health conditions. Vaccination is recommended for these high-risk groups, further driving demand for viral vaccines.

Infection Insights

In 2022, the Global Respiratory Disease Vaccine Market largest share was held by COVID-19 segment and is predicted to continue expanding over the coming years.  The COVID-19 pandemic created an unprecedented global demand for vaccines to combat the spread of the virus. COVID-19 is primarily a respiratory disease, and the urgency to develop and distribute effective vaccines to control the pandemic led to substantial investments in COVID-19 vaccine development. Governments and healthcare organizations worldwide prioritized COVID-19 vaccination as a critical component of their pandemic response efforts. Massive vaccination campaigns were launched to reach large segments of the population. The COVID-19 vaccines, including those from Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, and others, saw rapid development and production scale-up. This scale of vaccine production significantly contributed to the segment's market share. COVID-19 vaccines were distributed on a global scale, reaching both developed and developing countries. Governments and international organizations worked to secure vaccine supplies and distribute them widely.

Distribution Channel Insights

In 2022, the Global Respiratory Disease Vaccine Market largest share was held by hospital and retail pharmacies segment in the forecast period and is predicted to continue expanding over the coming years.  Hospitals and retail pharmacies are easily accessible to the general population. Patients often visit hospitals for routine check-ups, treatments, and vaccinations. Retail pharmacies, on the other hand, are widely distributed in urban and rural areas, making them convenient locations for vaccine administration. Healthcare providers, including doctors and nurses, play a crucial role in recommending and administering vaccines. Hospitals are primary healthcare settings where patients receive recommendations for vaccination, and vaccines are administered during hospital visits. Hospitals are frequently used as vaccination centres during large-scale vaccination campaigns organized by governments and healthcare organizations. For example, flu vaccination campaigns often involve hospitals as key distribution points. Respiratory diseases are more common among the elderly population. Many elderly individuals receive healthcare services in hospitals, and hospitals are more likely to have specialized departments for geriatric care, where vaccination is routinely offered.


Download Free Sample Report

Regional Insights

The Asia Pacific region held the largest market share in the Global Respiratory Disease Vaccine Market in 2022. The Asia Pacific region is home to a substantial portion of the world's population, including densely populated countries like China and India. The sheer number of people in the region creates a significant market for respiratory disease vaccines. Many countries in the Asia Pacific have been experiencing economic growth, leading to increased healthcare spending. This has allowed for greater investment in healthcare infrastructure, including vaccination programs. Awareness about the importance of vaccination has been on the rise in the Asia Pacific region. Governments and healthcare organizations have been actively promoting immunization, including respiratory disease vaccines, to combat the burden of preventable diseases. Like many other regions, the Asia Pacific is experiencing demographic changes with a growing aging population. Older adults are more susceptible to respiratory diseases, such as influenza and pneumonia, driving the demand for vaccines.

Recent Developments

  • In May 2023, Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for ABRYSVO™ (Respiratory Syncytial Virus Vaccine), Pfizer's bivalent RSV prefusion F (RSVpreF) vaccine, intended for the prevention of lower respiratory tract disease caused by RSV in individuals aged 60 and above. ABRYSVO is an unadjuvanted vaccine comprising two preF proteins carefully chosen to optimize protection against both RSV A and B strains, demonstrating safety and efficacy. The FDA's decision is rooted in data obtained from the pivotal Phase 3 clinical trial (NCT05035212) known as RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a globally conducted, randomized, double-blind, and placebo-controlled study aimed at evaluating the vaccine's effectiveness, immunogenicity, and safety when administered as a single dose to adults aged 60 and older.
  • In May 2023, The U.S. Food and Drug Administration (FDA) has granted approval for Arexvy, marking it as the first vaccine for respiratory syncytial virus (RSV) to be authorized for use in the United States. Arexvy's approval is specifically for the prevention of lower respiratory tract disease (LRTD) caused by RSV among individuals aged 60 years and older. RSV is a highly contagious virus responsible for lung and respiratory infections across all age groups. Typically, RSV exhibits seasonal circulation, commencing in the fall and reaching its peak during the winter months. In older adults, RSV stands as a frequent cause of lower respiratory tract disease (LRTD), characterized by lung-related issues, including potentially life-threatening conditions such as pneumonia and bronchiolitis, involving the inflammation of small airway passages in the lungs.
  • In July 2023, AstraZeneca and Sanofi have received approval in the United States for Beyfortus (nirsevimab), which is designed for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). This approval applies to newborns and infants who are either born during or entering their initial RSV season, as well as children up to 24 months old who remain susceptible to severe RSV disease during their second RSV season. Beyfortus represents the first preventive option approved to safeguard a wide range of infants, including those born at full term, preterm, or those with specific health conditions that render them at risk for severe RSV disease. The vaccine can be administered as a single dose, offering flexibility for administration at the outset of the RSV season or shortly after birth for infants born during the RSV season.

Key Market Players

  • GSK plc.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • SINOVAC Biotech Ltd.
  • Bavarian Nordic A/S
  • Merck & Co., Inc.
  • AstraZeneca Plc.
  • Moderna Inc.

By Type

By Infection

By Distribution Channel

By Region

By Region
  • Viral Vaccine
  • Bacterial Vaccine
  • Combination Vaccine
  • COVID-19
  • Influenza
  • Respiratory Syncytial Virus (RSV)
  • Pneumonia
  • Others
  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Rest of Middle East

 

Report Scope:

In this report, the Global Respiratory Disease Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •     Respiratory Disease Vaccine Market, By Type:

o   Viral Vaccine

o   Bacterial Vaccine

o   Combination Vaccine

 

  •   Respiratory Disease Vaccine Market, By Infection:

o   COVID-19

o   Influenza

o   Respiratory Syncytial Virus (RSV)

o   Pneumonia

o   Others

  •     Respiratory Disease Vaccine Market, By Distribution Channel:

o   Hospital & Retail Pharmacies

o   Government Suppliers

o   Others

  • Respiratory Disease Vaccine Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Vaccine Market.

Available Customizations:

Global Respiratory Disease Vaccine Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Respiratory Disease Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Respiratory Disease Vaccine Market Outlook

5.1.  Market Size & Forecast

5.1.1.        By Value

5.2.  Market Share & Forecast

5.2.1.        By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine)

5.2.2.        By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Others)

5.2.3.        By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others)

5.2.4.        By Region

5.2.5.        By Company (2022)

5.3.  Market Map

6.    Asia Pacific Respiratory Disease Vaccine Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Type

6.2.2.        By Infection

6.2.3.        By Distribution Channel

6.2.4.        By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.        China Respiratory Disease Vaccine Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Type

6.3.1.2.2.           By Infection

6.3.1.2.3.           By Distribution Channel

6.3.2.        India Respiratory Disease Vaccine Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Type

6.3.2.2.2.           By Infection

6.3.2.2.3.           By Distribution Channel

6.3.3.        Australia Respiratory Disease Vaccine Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Type

6.3.3.2.2.           By Infection

6.3.3.2.3.           By Distribution Channel

6.3.4.        Japan Respiratory Disease Vaccine Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Type

6.3.4.2.2.           By Infection

6.3.4.2.3.           By Distribution Channel

6.3.5.        South Korea Respiratory Disease Vaccine Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Type

6.3.5.2.2.           By Infection

6.3.5.2.3.           By Distribution Channel

7.    Europe Respiratory Disease Vaccine Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Type

7.2.2.        By Infection

7.2.3.        By Distribution Channel

7.2.4.        By Country

7.3.  Europe: Country Analysis

7.3.1.        France Respiratory Disease Vaccine Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Type

7.3.1.2.2.           By Infection

7.3.1.2.3.           By Distribution Channel

7.3.2.        Germany Respiratory Disease Vaccine Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Type

7.3.2.2.2.           By Infection

7.3.2.2.3.           By Distribution Channel

7.3.3.        Spain Respiratory Disease Vaccine Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Type

7.3.3.2.2.           By Infection

7.3.3.2.3.           By Distribution Channel

7.3.4.        Italy Respiratory Disease Vaccine Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Type

7.3.4.2.2.           By Infection

7.3.4.2.3.           By Distribution Channel

7.3.5.        United Kingdom Respiratory Disease Vaccine Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Type

7.3.5.2.2.           By Infection

7.3.5.2.3.           By Distribution Channel

8.    North America Respiratory Disease Vaccine Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Type

8.2.2.        By Infection

8.2.3.        By Distribution Channel

8.2.4.        By Country

8.3.  North America: Country Analysis

8.3.1.        United States Respiratory Disease Vaccine Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Type

8.3.1.2.2.           By Infection

8.3.1.2.3.           By Distribution Channel

8.3.2.        Mexico Respiratory Disease Vaccine Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Type

8.3.2.2.2.           By Infection

8.3.2.2.3.           By Distribution Channel

8.3.3.        Canada Respiratory Disease Vaccine Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Type

8.3.3.2.2.           By Infection

8.3.3.2.3.           By Distribution Channel

9.    South America Respiratory Disease Vaccine Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Type

9.2.2.        By Infection

9.2.3.        By Distribution Channel

9.2.4.        By Country

9.3.  South America: Country Analysis

9.3.1.        Brazil Respiratory Disease Vaccine Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Type

9.3.1.2.2.           By Infection

9.3.1.2.3.           By Distribution Channel

9.3.2.        Argentina Respiratory Disease Vaccine Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Type

9.3.2.2.2.           By Infection

9.3.2.2.3.           By Distribution Channel

9.3.3.        Colombia Respiratory Disease Vaccine Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Type

9.3.3.2.2.           By Infection

9.3.3.2.3.           By Distribution Channel

10. Middle East and Africa Respiratory Disease Vaccine Market Outlook

10.1.             Market Size & Forecast

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Type

10.2.2.     By Infection

10.2.3.     By Distribution Channel

10.2.4.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa Respiratory Disease Vaccine Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Type

10.3.1.2.2.         By Infection

10.3.1.2.3.         By Distribution Channel

10.3.2.     Saudi Arabia Respiratory Disease Vaccine Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Type

10.3.2.2.2.         By Infection

10.3.2.2.3.         By Distribution Channel

10.3.3.     UAE Respiratory Disease Vaccine Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Type

10.3.3.2.2.         By Infection

10.3.3.2.3.         By Distribution Channel

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Respiratory Disease Vaccine Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   GSK plc.

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Johnson & Johnson Services, Inc.

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   Pfizer Inc.

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   Sanofi SA

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   Serum Institute of India Pvt. Ltd.

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   Sinovac Biotech Ltd.

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Bavarian Nordic A/S

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

16.8.   Merck & Co., Inc.

16.8.1.     Business Overview

16.8.2.     Company Snapshot

16.8.3.     Products & Services

16.8.4.     Financials (In case of listed companies)

16.8.5.     Recent Developments

16.8.6.     SWOT Analysis

16.9.   AstraZeneca Plc.

16.9.1.     Business Overview

16.9.2.     Company Snapshot

16.9.3.     Products & Services

16.9.4.     Financials (In case of listed companies)

16.9.5.     Recent Developments

16.9.6.     SWOT Analysis

16.10.Moderna Inc.

16.10.1.  Business Overview

16.10.2.  Company Snapshot

16.10.3.  Products & Services

16.10.4.  Financials (In case of listed companies)

16.10.5.  Recent Developments

16.10.6.  SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Respiratory Disease Vaccine Market was estimated to be USD 91.80 billion in 2022.

down-arrow

GSK plc., Johnson & Johnson Services, Inc are some of the key players operating in the Respiratory Disease Vaccine Market.

down-arrow

Addressing public concerns and combating misinformation is an ongoing challenge in promoting respiratory disease vaccines.

down-arrow

Pneumococcal vaccines for pneumonia and other respiratory infections were gaining prominence.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Respiratory Disease Vaccine Market to grow with a CAGR of 1.18%

Nov, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Respiratory Disease Vaccine Market.

Why Choose Us